Welcome to Advanced Search

Models

About 43 results
Literature

4-Phenylbutyrate restored γ-aminobutyric acid uptake and reduced seizures in SLC6A1 patient variant-bearing cell and...

Model Organisms:小鼠 Product & Service:Slc6a1-S295L(NM-KI-190014) Research field:Rare disease

Pages

SMOC Launched U-HuDTMbase®, Inclusive Resource Library of Innovative Therapeutic Target-Humanized Mouse Models, to Accelerate Novel Drug Discovery

U-HuDTMbase® is composed of more than 600 therapeutic target-humanized mouse models, including multiple background strains, and has covered almost all commonly studied areas, such as oncology, metabolism, immunity, inflammation and more.

Pages

Join Our Webinar: Applications of Humanized Mouse Models in Preclinical Research

Humanized mouse models preclinical research targeted therapies webinar oncology drug development preclinical therapeutic advancements immune system models animal modeling services

Join GenoBioTX's webinar on July 25th to explore the latest advancements in humanized mouse models for preclinical research. Learn how these models are transforming targeted therapy development across various diseases. Featuring expert insights from Dr. Derek Reznik, discover the generation and application of humanized immune system models in oncology drug development. Don't miss this opportunity to enhance your knowledge in cutting-edge preclinical therapeutic advancements. Register now!

Pages

New Service Launch: Mouse Bone Metastasis Cancer Model and Pain-Related Behavior Assessment!

Bone metastasis cancer model Pain-related behavior assessment Cancer-induced bone pain Bone cancer pain models Mouse bone metastasis model Animal models in cancer research Cancer research services Bone metastasis in mice Pain management in cancer

We are excited to announce that GenoBioTX has launched a new service featuring mouse bone metastasis cancer models and pain-related behavior assessment, designed to support cancer research and pain management effectively.

Pages

Liver Cancer PDX Model

PDX PDX models Patient-derived Xenografts

Patient-derived Xenografts (PDX) are advanced preclinical oncology models for drug development. It offers a far better alternative for preclinical drug evaluation as compared to the conventional cell line-derived xenograft model.

Pages

Mouse models for cancer research

Tumor bearing Mouse DEN model PDX model CDX model

Shanghai Model Organisms Center provides multiple types of tumor-bearing mouse models for cancer research and drug efficacy testing, including cell line-derived xenograft model (CDX) and patient-derived xenograft model (PDX). While PDX models better reflect the heterogeneity and diversity of human cancers, CDX models allow researchers to advance their pre-clinical drug development in a cost- and time-efficient manner.

Pages

Cancer Model

research on cancer cancer model mouse models of cancer

The laboratory mouse is widely considered as a valid and affordable model organism for studying human disease. Mouse models of cancer not only enable researchers to understand the genetic basis of tumor development in complicated and dynamic physiological systems, but also serve as irreplaceable tools for developing and testing new therapies.  Shanghai Model Organisms Center offers a variety of mouse models of cancer to meet the needs of both academic and industry partners.

Pages

Evaluating the Efficacy of Tumor-targeted Antibody in vivo

immunotherapy immune checkpoint immune checkpoint genes

As the most frequently used animal model, mice have been widely applied in the evaluation of drug efficacy. However, the human immune checkpoint genes only share ~60% identity with their murine counterparts. Thus antibodies that recognize human proteins do not necessarily interact with murine proteins, making it inappropriate to use wild type mice for evaluating the in vivo efficacy of human-specific antibody. The humanized immune checkpoint mouse models (Immune-Hu models), which were independently developed by Shanghai Model Organisms Center, are ideal models to evaluate the efficacy of anti-tumor antibody therapy.

Email Back to top